FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000318498> ?p ?o ?g. }

• W2000318498 endingPage "56" @default.
• W2000318498 startingPage "45" @default.
• W2000318498 abstract "The considerable research efforts devoted to the understanding of the mechanisms of tumor angiogenesis have resulted in the development of targeted anti-angiogenic therapies and finally in their introduction in clinical practice. Neuroendocrine tumors (NETs), which are characterized by a high vascular supply and a strong expression of VEGF-A, one of the most potent pro-angiogenic factors, are an attractive indication for these new treatments. However, several lines of evidence show that the dense vascular networks associated with low-grade NETs are more likely to be a marker of differentiation than a marker of aggressiveness, as in other epithelial tumors. These observations form the basis for the so-called ‘neuroendocrine paradox’, according to which the most vascularized are the most differentiated and the less angiogenic NETs. This must be kept in mind when discussing the role of anti-angiogenic strategies in the treatment of NETs. Nevertheless, several targeted therapies, with direct or indirect anti-angiogenic properties, including anti-VEGF antibodies, tyrosine kinase inhibitors (sunitinib) and mTOR inhibitors (everolimus), have recently proven to be of clinical benefit. In addition, some drugs already used in NET treatment, such as somatostatin analogues and interferon-α, may also have anti-angiogenic properties. The main challenges for the next future are to validate biomarkers for the selection of patients and the prediction of their response to refine the indications of anti-angiogenic targeted therapies and to overcome the mechanisms of resistance, which explain the limited duration of action of most of these treatments." @default.
• W2000318498 created "2016-06-24" @default.
• W2000318498 creator A5042575799 @default.
• W2000318498 date "2012-04-25" @default.
• W2000318498 modified "2023-10-17" @default.
• W2000318498 title "Angiogenesis in Neuroendocrine Tumors: Therapeutic Applications" @default.
• W2000318498 cites W1492420498 @default.
• W2000318498 cites W1497202669 @default.
• W2000318498 cites W1592045168 @default.
• W2000318498 cites W1966065114 @default.
• W2000318498 cites W1966535797 @default.
• W2000318498 cites W1967600348 @default.
• W2000318498 cites W1967988142 @default.
• W2000318498 cites W1970107343 @default.
• W2000318498 cites W1970248216 @default.
• W2000318498 cites W1975442922 @default.
• W2000318498 cites W1977999028 @default.
• W2000318498 cites W1978094785 @default.
• W2000318498 cites W1981791928 @default.
• W2000318498 cites W1981847035 @default.
• W2000318498 cites W1982937951 @default.
• W2000318498 cites W1982981835 @default.
• W2000318498 cites W1984383995 @default.
• W2000318498 cites W1985804036 @default.
• W2000318498 cites W1988631826 @default.
• W2000318498 cites W1989401206 @default.
• W2000318498 cites W1991773600 @default.
• W2000318498 cites W1992049575 @default.
• W2000318498 cites W1993016882 @default.
• W2000318498 cites W1996480660 @default.
• W2000318498 cites W1997796798 @default.
• W2000318498 cites W1998629360 @default.
• W2000318498 cites W1999985162 @default.
• W2000318498 cites W2000194757 @default.
• W2000318498 cites W2011022421 @default.
• W2000318498 cites W2015547104 @default.
• W2000318498 cites W2015809080 @default.
• W2000318498 cites W2016569548 @default.
• W2000318498 cites W2017082986 @default.
• W2000318498 cites W2017322644 @default.
• W2000318498 cites W2026351725 @default.
• W2000318498 cites W2026619724 @default.
• W2000318498 cites W2032995169 @default.
• W2000318498 cites W2039155298 @default.
• W2000318498 cites W2042337927 @default.
• W2000318498 cites W2043580837 @default.
• W2000318498 cites W2046507292 @default.
• W2000318498 cites W2050329813 @default.
• W2000318498 cites W2053262936 @default.
• W2000318498 cites W2055359615 @default.
• W2000318498 cites W2056408500 @default.
• W2000318498 cites W2057103712 @default.
• W2000318498 cites W2057866936 @default.
• W2000318498 cites W2058387514 @default.
• W2000318498 cites W2066524125 @default.
• W2000318498 cites W2067216473 @default.
• W2000318498 cites W2068562114 @default.
• W2000318498 cites W2070338369 @default.
• W2000318498 cites W2072292497 @default.
• W2000318498 cites W2072578327 @default.
• W2000318498 cites W2076704022 @default.
• W2000318498 cites W2079251713 @default.
• W2000318498 cites W2079579097 @default.
• W2000318498 cites W2079884000 @default.
• W2000318498 cites W2081704237 @default.
• W2000318498 cites W2081887573 @default.
• W2000318498 cites W2088269008 @default.
• W2000318498 cites W2088601895 @default.
• W2000318498 cites W2090941518 @default.
• W2000318498 cites W2094078468 @default.
• W2000318498 cites W2094784951 @default.
• W2000318498 cites W2094962376 @default.
• W2000318498 cites W2095317693 @default.
• W2000318498 cites W2098482546 @default.
• W2000318498 cites W2098681351 @default.
• W2000318498 cites W2100601793 @default.
• W2000318498 cites W2101037339 @default.
• W2000318498 cites W2102047778 @default.
• W2000318498 cites W2102056525 @default.
• W2000318498 cites W2103928688 @default.
• W2000318498 cites W2104970412 @default.
• W2000318498 cites W2110066617 @default.
• W2000318498 cites W2112064092 @default.
• W2000318498 cites W2114650321 @default.
• W2000318498 cites W2115686439 @default.
• W2000318498 cites W2119281341 @default.
• W2000318498 cites W2119821919 @default.
• W2000318498 cites W2123312554 @default.
• W2000318498 cites W2124412218 @default.
• W2000318498 cites W2125153669 @default.
• W2000318498 cites W2126446022 @default.
• W2000318498 cites W2127456497 @default.
• W2000318498 cites W2128267006 @default.
• W2000318498 cites W2128879260 @default.
• W2000318498 cites W2131705241 @default.
• W2000318498 cites W2132272301 @default.
• W2000318498 cites W2134701016 @default.
• W2000318498 cites W2137000011 @default.

• next